Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
As of the April data cutoff, the survival rate at two years in the GBM trial for unmethylated MGMT (uMGMT) patients remained consistent at 29% with median overall survival holding steady at 17 months. In historical cohorts, uMGMT patients receiving standard of care have shown a two-year survival rate of approximately 14% and a median overall survival of 13 to 15 months.
In parallel, the TEM-GU Phase 1 study—designed to enroll 12 patients with genitourinary tumors—has begun recruitment. In this trial, Temferon is administered at a fixed dose of 4 million genetically modified cells per kilogram of body weight—a level previously shown to be safe and well tolerated in the TEM-GBM dose-ranging study. Genenta aims to demonstrate the safety and tolerability of Temferon in patients with Metastatic Renal Cell Carcinoma by year-end. The study is designed to evaluate Temferon in combination with immune checkpoint inhibitors or tyrosine kinase inhibitors to assess the potential for immunologic synergy in this patient population. Further clinical updates will be shared once sufficient patient experience has been gained to support meaningful interpretation.
Temferon's mechanism of action is based on the reprogramming of the tumor microenvironment, which promotes the activation and durability of adaptive immune responses. A scientific manuscript demonstrating Temferon's potential to enhance and prolong the durability of CAR-T activity in preclinical murine models of solid tumors has been accepted for publication in Science Translational Medicine.
' For the first time, we show that hematopoietic stem cells can be engineered to durably give rise to myeloid cells that localize to the tumor and reprogram its immune environment. In glioblastoma, this strategy induced a pro-inflammatory shift in macrophages and the emergence of tumor-reactive T cells, offering a promising new avenue for immune engagement against one of the most resistant cancers, ' said prof. Luigi Naldini, co-founder of Genenta Science.
' We are encouraged by the consistent clinical signals emerging from our glioblastoma trial, ' said Pierluigi Paracchi, CEO of Genenta Science. 'T hese findings reinforce our confidence in Temferon's differentiated mechanism and support our commitment to advancing the platform. '
About Genenta Science
Genenta Science (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genenta's first in class product candidate is Temferon™, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow derived myeloid cells and enable a durable and targeted response. Genenta has completed the Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibiting of myeloid induced tolerance, while allowing the induction of T cell responses, potentially breaking immune tolerance. Genenta has initiated a Phase 1/2a metastatic Renal Cell Carcinoma study that will also include a combination with immune checkpoint inhibitors. Genenta's treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.
Forward-Looking Statements
Statements in this press release contain 'forward-looking statements,' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'suggest,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the funding provided by the recently acquired Mandatory Convertible Bond, the completion and timing of Genenta's ongoing Phase 1/2a clinical trial for newly diagnosed GBM patients with uMGMT-GBM, its clinical trial for metastatic RCC or any related studies, as well as Genenta's ability to fund its research and development plans. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in Genenta's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law. This press release discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processes. No representation is made as to the safety or effectiveness of these product candidates or the use for which such product candidates are being studied. Temferon™ is an investigational product candidate for which the effectiveness and safety have not been established. In addition, Temferon™ is not approved for use in any jurisdiction.
Genenta Science Media
Tiziana Pollio, Mobile: +39 348 23 15 143
E-mail: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Oscar Health, Thoma Bravo & Verint, Apple: Trending Tickers
Oscar Health (OSCR) stock falls after Barclays analysts initiated coverage of the stock with an Underweight rating. Oscar Health was also downgraded to Market Perform from Outperform by Raymond James. Buyout firm Thoma Bravo is reportedly in talks to buy Verint Systems (VRNT), according to Bloomberg. Apple (AAPL) was upgraded to Hold from Underperform by Jefferies analysts, who also increased their price target for the stock. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts here. Time now for some of today's trending tickers. We are watching Oscar Health, Verint Systems, and Apple. First up, Oscar Health shares plummeting today. Barclays initiating coverage of the stock with an underweight rating, citing policy risks that could impact the health insurance company's growth and margins. Raymond James also downgrading the stock to market perform from outperform, also citing policy risks. Says tariffs, expiring subsidies and funding cuts weigh on sentiment in the healthcare industry. Meanwhile, Verint Systems is soaring on the back of a Bloomberg report that buyout firm Thoma Bravo is in talks to acquire the company. Verint is a New York-based company that makes call center software, and according to its website, it's a leader in customer experience automation and serves about 10,000 blue chip customers in more than 175 countries. The company has been listed on the Nasdaq Stock Exchange since 2002, Nasdaq stock market. And finally, Apple getting an upgrade at Jeffries to hold from underperform and a price target raised to over $188 from $171. The firm saying that it believes strong third quarter earnings could, quote, keep the stock stable near term. Weak iPhone sales and problems developing artificial intelligence services has dragged on Apple stock this year. Shares are down about 15% since January. You can scan the QR code below to track the best and worst performing stocks with Yahoo Finance's Trending Tickers page. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
an hour ago
- Fox News
Beach bacteria warnings plague Fourth of July weekend plans nationwide
Americans heading to the beach for Independence Day weekend may want to check if the waters are OK for swimming or wading. Warnings of high bacteria levels from public health officials have begun popping up in various states coast to coast. Vibrio is a bacterium that naturally lives in coastal waters, causing fever, vomiting, diarrhea, and cramps, according to the U.S. Centers for Disease Control and Prevention (CDC). On the West Coast, California officials in San Diego issued many warnings and closures of popular beaches, noting that some "bacteria levels exceed health standards." Two counties in Long Island, New York, have issued similar advisories. Suffolk County health officials posted, "Benjamin Beach in Bay Shore, Ronkonkoma Beach in the Town of Islip, and Sayville Marina Park Beach in Sayville are closed to bathing due to the finding of bacteria at levels in excess of acceptable criteria." The beaches will reopen when further testing reveals bacteria levels have dropped to acceptable levels, said the press release. Three Nassau County beaches — Hewlett Point, Island Park, and Phillip Healey Beach — are under advisory after heavy rainfall, according to the Nassau County Department of Health (NCDOH). Beaches will reopen when further testing reveals bacteria levels have dropped to acceptable levels. "Stormwater runoff may have impacted water quality at 3 South Shore beaches. As a precaution, NCDOH is advising against swimming at these locations. Stormwater runoff can raise bacteria levels, possibly exceeding NYS standards for safe bathing," said an NCDOH press release. In Massachusetts, nearly 20 beaches were closed as of Wednesday morning. Seventeen beaches are listed on the Massachusetts Department of Health "Beaches Dashboard," due to bacteria levels. Washington state lists advisories to "stay out of the water" at seven beaches with "high bacteria" in King County, according to its website. The Prairie State lists 34 advisories on their Illinois government website. There are 80,000 cases of the infection reported each year, according to the CDC. Michigan has nine beaches closed due to high bacteria levels from "wildlife" and "storm water runoff." Four beaches in the Great Lake State also have contamination advisories.
WIRED
an hour ago
- WIRED
With RFK Jr. in Charge, Insurers Aren't Saying If They'll Cover Vaccines for Kids If Government Stops Recommending Them
Jul 2, 2025 10:25 AM RFK Jr.'s vaccine advisory board could stop recommending some routine childhood immunizations, leaving insurers to decide whether to still cover them. For now, most are remaining tight-lipped. Photograph:In the wake of the Advisory Committee on Immunization Practices (ACIP) announcing plans to revisit its recommended schedule for childhood vaccinations—a move that has drawn widespread criticism from experts—major insurers have not confirmed whether they'll continue to cover the full cost of routine shots for children. For 60 years ACIP has provided vaccine guidance to the Centers for Disease Control and Prevention (CDC), including on the timing and dosage of childhood immunizations. Insurers are required to cover the cost of most jabs on the recommended schedule for children. On Wednesday June 25, ACIP announced it would review the schedule, just weeks after health secretary and longtime anti-vaccine activist Robert F. Kennedy Jr. replaced the entire committee with his own appointees. When WIRED then asked 21 of the country's largest health insurance groups whether they would stop providing cost-free coverage of current routine immunizations in the event ACIP stops recommending them, only Blue Shield of California—a company in the Blue Cross Blue Shield Association—confirmed it would. 'As a payer our role is to ensure ongoing coverage and access to preventive, evidence-based care, including immunizations,' says company spokesperson Mark Seelig. 'Therefore, Blue Shield of California is committed to maintaining coverage of immunizations. The decision on whether to receive a vaccine is between our member and their provider.' Other large insurers, including UnitedHealthcare (which provides coverage for 50 million people), Cigna, Kaiser Permanente, Anthem, Humana, and Centene Corporation, did not respond to requests for comment. Blue Cross Blue Shield of Michigan said it had no comment. Most insurers that did respond said they were keeping an eye on developments in Washington, without indicating whether they would or would not cover vaccines dropped from the recommended schedule. 'Vaccines play an important role in the prevention of more serious illnesses,' says Phil Blando, a spokesperson at CVS Health, which owns the insurer Aetna. 'We are monitoring any changes the federal government makes to vaccination guidance and eligibility and will evaluate whether coverage adjustments are needed.' Highmark Inc., part of the Blue Cross Blue Shield Association, operating in Pennsylvania, Delaware, West Virginia, and New York, is also waiting to see what decision ACIP reaches. 'We are closely monitoring the evolving vaccine discussions occurring in Washington, DC. Various vaccines and immunizations are covered under Highmark's member benefits, with any future coverage considerations to be evaluated as more information becomes available,' says spokesperson Aaron Billger. Bryan Campen, of Health Care Service Corporation—the licensee of Blue Cross Blue Shield plans in Illinois, Montana, New Mexico, Oklahoma, and Texas—notes that no changes have yet been made to the vaccines ACIP recommends or the company's vaccine coverage, but says that the company will 'continue to monitor any activity that may impact preventive care recommendations and will communicate any changes to recommendations that may impact standard coverage of preventive services.' Insurers had an eye on changes in ACIP guidance even before the committee announced it would revisit the schedule. 'As we navigate an evolving health care landscape, maintaining robust immunization coverage continues to be a top priority for protecting both individual and community health,' the industry's trade association, AHIP, said in a June 24 statement, the day before ACIP's announcement. 'We are committed to ongoing coverage of vaccines to ensure access and affordability for this respiratory virus season,' the statement continued. 'We encourage all Americans to talk to their health care provider about vaccines.' ACIP made headlines in early June when RFK Jr. fired all 17 of its members and replaced them with eight new appointees. (The HHS secretary appoints the committee's members, but conventionally they serve fixed 4-year terms.) These new appointees include Retsef Levi, who has stated—in the face of scientific consensus—that mRNA vaccines are deadly, and Robert Malone, who routinely shares articles about supposed links between cancer and the Covid vaccine, which no credible research has found to exist. Neither Levi nor Malone replied to a request for comment. Michael A. Ross, another recently appointed committee member, resigned from ACIP during a review of his financial holdings, the New York Times reported on June 24. When introducing his new ACIP appointees in a post on X earlier in June, RFK Jr. had described Ross as a faculty member at George Washington and Virginia Commonwealth universities—but spokespeople for the universities told NBC News4 that Ross had not taught at either in years. Ross did not reply to a request for comment. The committee made news again on June 25 when, during its first meeting of the year, it announced it would form a working group to review the recommended immunization schedule for children and teens. 'The number of vaccines that our children and adolescents receive today exceed what children in most other developed nations receive, and what most of us in this room received when we [were] children,' ACIP chair Martin Kulldorff said during the meeting. He noted that the group would examine the 'cumulative effect' of the recommended vaccine schedule, including interactions between vaccines, the total number of vaccines given, their timing, and recipients' exposure to vaccine ingredients. But the process for adding vaccines to the schedule is already rigorous. Before a vaccine can receive FDA licensure, its manufacturer must prove it does not negatively affect the safety or immune response of other vaccines administered at the same time on the schedule, says Paul Offit, director of the Children's Hospital of Philadelphia's Vaccine Education Center. In addition, 'the notion that these vaccines are somehow weakening your immune system or overwhelming your immune system is fanciful,' Offit says. Today, children are exposed to fewer viral or bacterial proteins in the first few years of the vaccine schedule than those in earlier generations. When Offit's parents received the smallpox vaccine, they were exposed to 200 proteins in a single shot. In contrast, the measles vaccine only contains 10. During the meeting, Kulldorff repeated claims he made in 2024 that he was fired from Harvard because he refused to get the Covid vaccine; he and Malone have also each served as paid expert witnesses in two separate suits against Merck over the safety of the company's HPV vaccine and its mumps vaccine, respectively. Kulldorff did not reply to a request for comment. The American Academy of Pediatrics (AAP) did not send representatives to last week's ACIP meeting, as it typically does. According to Academy president Susan Kressly, this was because the AAP believes the vaccine recommendation process lost credibility when its original membership was gutted by Kennedy. 'We won't lend our name or our expertise to a system that is being politicized at the expense of children's health,' Kressly said in a video posted online before the meeting was set to begin. The AAP did not reply to a request for comment about the video. The most recent child immunization schedule that the AAP endorses, from November 2024, is posted on the AAP website. A newer one, posted on the CDC site, has already changed recommendations. It no longer lists as 'routine' Covid vaccines for children under 18 who are not immunocompromised, but instead lists them under vaccines recommended for 'shared clinical decision-making,' informed by 'personal preference and circumstances.' The change should not affect insurance coverage.
